Dry Eye News and Research

RSS
Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.
Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Parents severely underestimate time children spend on digital devices

Parents severely underestimate time children spend on digital devices

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Rand Eye Institute's hurricane eye safety tips

Rand Eye Institute's hurricane eye safety tips

Computer simulations offer potential treatment option for dry eye syndrome

Computer simulations offer potential treatment option for dry eye syndrome

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

New research aids development of better treatments for dry eye

New research aids development of better treatments for dry eye

FDA approves Parion’s investigational new drug application for treatment of dry eye disease

FDA approves Parion’s investigational new drug application for treatment of dry eye disease

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals completes $22.5 million Series B financing

New report reveals potential breakthrough in pterygium treatment

New report reveals potential breakthrough in pterygium treatment

SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.